ONCODESIGN news, videos and press releases
For more news please use our advanced search feature.
ONCODESIGN - More news...
ONCODESIGN - More news...
- Oncodesign Services, a Leading European CRO In Preclinical Drug Discovery Acquires ZoBio, A CRO Specialized in Small Molecule Drug Discovery
- EDMOND DE ROTHSCHILD EQUITY STRATEGIES IV, Advised By ELYAN PARTNERS, Acquires a Majority Stake in ONCODESIGN SERVICES and Will File a Simplified Tender Offer on the Company's Remaining Shares
- Oncodesign Precision Medicine (OPM) Announces its IPO Through Direct Listing on Euronext Access + Paris
- The General Meeting of Oncodesign Authorises the Allocation of Oncodesign Precision Medicine (OPM) Shares to Oncodesign Shareholders
- Euronext Paris Authorises the Listing of Oncodesign Precision Medicine (OPM) Shares on Euronext Access + in Connection With the Allocation of OPM Shares to Oncodesign Shareholders
- Servier Exercises the Exclusive Worldwide License Option of Their Collaboration Program With Oncodesign Precision Medicine (OPM) on Parkinson's disease
- Oncodesign Precision Medicine (OPM) and Servier Announce a Strategic Collaboration to Discover New Therapeutic Targets for Pancreatic Cancer Treatment
- Oncodesign Announces Its Results for the First Half of 2022: 28% Growth in Service Turnover
- Oncodesign Continues to Grow With a Strong Increase in Its Service Activity’s Turnover in the First Half of 2022
- ONCODESIGN Announces the Separation of Its Two Business Lines – Service and Biotech – and Its Entry Into Exclusive Negotiations With Elyan Partners for the Sale of a Majority Stake in ONCODESIGN (Service), Followed by a Simplified Takeover Offer
- Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022
- SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors
- Oncodesign Announces a 2021 Turnover of €31.3M, up by 22%, and Expects to Break Even
- ONCODESIGN Announces Its 2022 Financial Agenda
- Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bowel Disease
- Oncodesign Has Appointed Karine Lignel as Group Chief Development Officer
- Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates
- Oncodesign Announces Its Results for the First Half of 2021
- Oncodesign Announces a Sharp Increase in Turnover in the First Half Of 2021
- Oncodesign Announces the Appointment of Aline Aubertin as an Independent Director of the Board of Directors
- Oncodesign Launches its New DRIVE-MRT™ Service Offer in Partnership with Covalab, CheMatech and ABX-CRO
- Oncodesign Provides an Update on Its Progress On RIPK2
- Servier and Oncodesign Announce the Selection of a Preclinical Candidate as Part of Their Collaboration Targeting New Treatments for Parkinson’s Disease
- InterSystems and Oncodesign Partner for the Optimization of Data Use to Enhance and Accelerate Drug Discovery Processes in Oncology
- Oncodesign Records Positive Profitability for the Second Straight Year and Doubles Its Operating Profit Within the Context of the Global Health Crisis
- Oncodesign Maintains Its Revenue and Operating Income at €38 Million in 2020 and is Anticipating an Operating Profit for the 2nd Straight Year, Within the Context of the Global Public Health Crisis
- Oncodesign Announces a Share Ownership Plan for All Employees on the Occasion of the Group's 25th Anniversary
- Oncodesign Announces Drug Discovery Cooperation With ViraTherapeutics, a Boehringer Ingelheim Subsidiary
- Oncodesign Obtains €15.9 Million of Non-dilutive Financing in the Form of a State-Guaranteed Loan Within the Context of The COVID-19 Pandemic
- Oncodesign: First-half 2020 Results
